Skip to main content

Advertisement

Table 3 Multivariate Cox regression analysis for patient survival

From: MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

Entire cohort (N = 119) N of patients N of events Hazard ratio 95 % CI Wald’s p
 Performance status
  1–2–3 vs. 0 32 vs. 87 27 vs. 61 1.64 1.03–2.62 0.036
 TOP2A (FISH) ratio 2.0 copies 4.0
  Amplified vs. non-amplified 42 vs. 77 28 vs. 60 0.62 0.38–1.00 0.050
 MYC CN
  Gain vs. no gain 10 vs. 109 10 vs. 78 6.02 2.67–13.6 <0.001
 Type of disease*CEN profile (binary)      0.048
  CEN profile, 1chr vs. other @ R-mBC 28 vs. 58 24 vs. 39 2.29 1.36–3.85  
  CEN profile, 1chr vs. other @ de novo-mBC 12 vs. 21 9 vs. 16 0.77 0.29–2.04  
  de novo-mBC vs. R-mBC @ CEN profile, other 21 vs. 58 16 vs. 39 1.15 0.64–2.08  
  de novo-mBC vs. R-mBC @ CEN profile, 1chr 12 vs. 28 9 vs. 24 0.39 0.16–0.93  
HER2-positive (N = 83)
 TOP2A (FISH) ratio 2.0 copies 4.0
  Amplified vs. non-amplified 39 vs. 44 25 vs. 35 0.58 0.35–0.98 0.041
 MYC CN
  Gain vs. no gain 7 vs. 76 7 vs. 53 4.40 1.90–10.2 0.001
HER2-negative (N = 45)
 Menopausal status
  Post vs. pre 28 vs. 17 25 vs. 10 3.69 1.57–8.65 0.003
 ER/PgR
  Positive vs. negative 39 vs. 6 29 vs. 6 0.22 0.08–0.58 0.002
 MYC FISH binary (ratio 2, copies >5)
  Amplified vs. non-amplified 4 vs. 41 4 vs. 31 4.54 1.40–14.70 0.012
 Ki67 (by increase 5 %)    1.16 1.07–1.26 0.001
R-mBC (N = 84)
 Age
  ≥50 vs. <50 56 vs. 28 39 vs. 23 0.50 0.28–0.89 0.019
 Performance status
  1-2-3 vs. 0 25 vs. 59 22 vs. 40 1.83 1.07–3.14 0.028
 ER/PgR
  Positive vs. negative 57 vs. 27 39 vs. 23 0.43 0.24–0.76 0.004
 PI3K
  Activation vs. non-activation 74 vs. 10 56 vs. 6 4.50 1.63–12.39 0.004
 MYC CN
  Gain vs. no gain 6 vs. 78 6 vs. 56 20.48 6.77–61.99 <0.001
de novo-mBC (N = 49)
 Performance status
  1-2-3 vs. 0 13 vs. 36 12 vs. 26 1.99 0.99–4.02 0.055
 ER/PgR
  Positive vs. negative 36 vs. 13 27 vs. 11 0.16 0.03–0.77 0.023
 HER2 status/subtypes      0.13
  Luminal HER2 vs. HER2-negative 21 vs. 17 16 vs. 13 1.15 0.53–2.49 0.72
  HER-enriched vs. HER2-negative 11 vs. 17 9 vs. 13 0.20 0.04–0.96 0.045
  1. N number, CI confidence interval, CN copy number, italics unfavorable, bold italics favorable prediction